Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Flagstar Bank NA (FLG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Flagstar Bank NA — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Flagstar Bank NA trades at $15 (market cap $6.29B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6.3× Flagstar Bank NA's market cap, and Flagstar Bank NA pays a 0.27% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | FLG | |
|---|---|---|
Market Cap | $39.89B | $6.29B |
Sector | Health | Financials |
52-Week High | $491.22 | $15.28 |
52-Week Low | $278.09 | $10.72 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 0.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Flagstar Bank (FLG) trades at $15.09, up 2.17% today, with a neutral technical outlook and bullish analyst consensus. The stock shows improving fundamentals with two consecutive quarterly earnings beats and a modest dividend. Recent news highlights technology transformation and executive leadership stability, while financial trends indicate progress toward profitability despite current negative margins.
The outlook suggests moderate upside potential with a $17.05 consensus price target, though risks include ongoing negative profitability and high interest expenses. The bank's turnaround progress and improved credit quality provide catalysts, but investors should weigh the balance between valuation discount and execution risks in the competitive banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →
